{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:57:33Z","timestamp":1772773053500,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Classical Hodgkin lymphoma (cHL) is a highly curable disease, while novel therapy is needed for refractory or relapsed (R\/R) patients. This phase II trial aimed to evaluate the role of camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in R\/R cHL patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Transplant-eligible patients with R\/R cHL were enrolled and received two 14-day cycles of camrelizumab 200\u00a0mg intravenously (IV) and two 28-day cycles of camrelizumab 200\u00a0mg IV, gemcitabine 1000\u00a0mg\/m<jats:sup>2<\/jats:sup> IV, and oxaliplatin 100\u00a0mg\/m<jats:sup>2<\/jats:sup> IV on days 1 and 15. Patients with partial response (PR) or stable disease received an additional cycle of combination therapy. Those who achieved complete response (CR) or PR proceeded to autologous stem cell transplantation (ASCT). The primary endpoint was the CR rate at the end of protocol therapy before ASCT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty-two patients were enrolled. At the end of protocol therapy, the objective response rate and CR rate were 94.9% (37\/39) and 69.2% (27\/39) in the evaluable set, and 88.1% (37\/42) and 64.3% (27\/42) in the full analysis set, respectively. Twenty-nine patients (69.0%) proceeded to ASCT, and 4 of 5 patients with PR achieved CR after ASCT. After a median follow-up of 20.7\u00a0months, the 12-month progression-free survival rate was 96.6% and the 12-month overall survival rate was 100%. Grade 3 or higher treatment emergent adverse events occurred in 28.6% of patients (12\/42), mainly hematological toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Camrelizumab combined with GEMOX constitutes an effective salvage therapy for R\/R cHL, proving to be relatively well-tolerated and facilitating ASCT in most patients, thus promoting sustained remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov NCT04239170. Registered on January 1, 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-024-03329-8","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T15:03:06Z","timestamp":1709823786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Yanfei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhitao","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feier","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningjing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meifeng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"3329_CR1","doi-asserted-by":"publisher","first-page":"6731","DOI":"10.2147\/CMAR.S324543","volume":"13","author":"R Nuersulitan","year":"2021","unstructured":"Nuersulitan R, Yang M, Mi L, Wu M, Liu X, Ping L, et al. Conditional survival and annual hazard estimates of classical Hodgkin lymphoma. Cancer Manag Res. 2021;13:6731\u201341.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"3329_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1100340","volume":"365","author":"S Viviani","year":"2011","unstructured":"Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned. New Engl J Med. 2011;365(3):203\u201312.","journal-title":"New Engl J Med"},{"issue":"9323","key":"3329_CR3","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359(9323):2065\u201371.","journal-title":"Lancet"},{"issue":"3","key":"3329_CR4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood.V97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616\u201323.","journal-title":"Blood"},{"issue":"3","key":"3329_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","volume":"16","author":"AJ Moskowitz","year":"2015","unstructured":"Moskowitz AJ, Schoder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284\u201392.","journal-title":"Lancet Oncol"},{"issue":"23","key":"3329_CR6","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","volume":"116","author":"AJ Moskowitz","year":"2010","unstructured":"Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934\u20137.","journal-title":"Blood"},{"key":"3329_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1182\/blood-2019-123925","volume":"134","author":"A Stamatoullas","year":"2019","unstructured":"Stamatoullas A, Ghesquieres H, Filliatre LC, Quittet P, Morschhauser F, Ribrag V, et al. Brentuximab vedotin in first refractory\/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. Final analysis of phase II study. Blood. 2019;134:132.","journal-title":"Blood"},{"issue":"4","key":"3329_CR8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/annonc\/mdz009","volume":"30","author":"R Garcia-Sanz","year":"2019","unstructured":"Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019;30(4):612\u201320.","journal-title":"Ann Oncol"},{"issue":"1","key":"3329_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40\u20138.","journal-title":"Blood"},{"key":"3329_CR10","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1182\/blood-2018-99-112235","volume":"132","author":"A Hagenbeek","year":"2018","unstructured":"Hagenbeek A, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, et al. Combining brentuximab vedotin with DHAP as salvage treatment in relapsed\/refractory Hodgkin lymphoma: the phase II HOVON\/LLPC transplant BRaVE study. Blood. 2018;132:2923.","journal-title":"Blood"},{"issue":"28","key":"3329_CR11","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.21.01056","volume":"39","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Shah G, Schoder H, Ganesan N, Drill E, Hancock H, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol. 2021;39(28):3109-#x0002B;","journal-title":"J Clin Oncol"},{"issue":"25","key":"3329_CR12","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1182\/blood.2022015423","volume":"139","author":"MG Mei","year":"2022","unstructured":"Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022;139(25):3605\u201316.","journal-title":"Blood"},{"issue":"3","key":"3329_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/ajh.26827","volume":"98","author":"SH Desai","year":"2023","unstructured":"Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, et al. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed\/refractory classic Hodgkin lymphoma. Am J Hematol. 2023;98(3):464\u201371.","journal-title":"Am J Hematol"},{"issue":"24","key":"3329_CR14","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","volume":"25","author":"Y Song","year":"2019","unstructured":"Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y, et al. A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. Clin Cancer Res. 2019;25(24):7363\u20139.","journal-title":"Clin Cancer Res"},{"key":"3329_CR15","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.2147\/OTT.S70264","volume":"7","author":"A Gutierrez","year":"2014","unstructured":"Gutierrez A, Rodriguez J, Martinez-Serra J, Gines J, Paredes P, Garcia F, et al. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. Oncotargets Ther. 2014;7:2093\u2013100.","journal-title":"Oncotargets Ther"},{"issue":"1","key":"3329_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","volume":"102","author":"WM Liu","year":"2010","unstructured":"Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Brit J Cancer. 2010;102(1):115\u201323.","journal-title":"Brit J Cancer"},{"issue":"18","key":"3329_CR17","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","volume":"11","author":"E Suzuki","year":"2005","unstructured":"Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1(+)\/CD11b(+) myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713\u201321.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3329_CR18","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1172\/JCI43656","volume":"121","author":"WJ Lesterhuis","year":"2011","unstructured":"Lesterhuis WJ, Punt CJA, Hato SV, Eleveld-Trancikova D, Jansen BJH, Nierkens S, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011;121(8):3100\u20138.","journal-title":"J Clin Invest"},{"issue":"13","key":"3329_CR19","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1038\/s41388-018-0581-9","volume":"38","author":"S Grabosch","year":"2019","unstructured":"Grabosch S, Bulatovic M, Zeng FTZ, Ma TZ, Zhang LX, Ross M, et al. Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. Oncogene. 2019;38(13):2380\u201393.","journal-title":"Oncogene"},{"key":"3329_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.oraloncology.2019.06.016","volume":"95","author":"SJ Park","year":"2019","unstructured":"Park SJ, Ye WD, Xiao R, Silvin C, Padget M, Hodge JW, et al. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. Oral Oncol. 2019;95:127\u201335.","journal-title":"Oral Oncol"},{"issue":"12","key":"3329_CR21","doi-asserted-by":"publisher","first-page":"e01039","DOI":"10.1016\/j.heliyon.2018.e01039","volume":"4","author":"XS Wu","year":"2018","unstructured":"Wu XS, Li YL, Liu X, Chen CH, Harrington SM, Cao SY, et al. Targeting B7\u2013H1 (PD-L1) sensitizes cancer cells to chemotherapy. Heliyon. 2018;4(12):e01039.","journal-title":"Heliyon"},{"issue":"21","key":"3329_CR22","doi-asserted-by":"publisher","first-page":"7830","DOI":"10.1002\/cam4.3262","volume":"9","author":"B Casadei","year":"2020","unstructured":"Casadei B, Argnani L, Morigi A, Lolli G, Broccoli A, Pellegrini C, et al. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma. Cancer Med-Us. 2020;9(21):7830\u20136.","journal-title":"Cancer Med-Us"},{"issue":"8","key":"3329_CR23","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ajh.25154","volume":"93","author":"C Rossi","year":"2018","unstructured":"Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a series from lysa centers. Am J Hematol. 2018;93(8):1042\u20139.","journal-title":"Am J Hematol"},{"issue":"6","key":"3329_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood.2020009178","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021;138(6):427\u201338.","journal-title":"Blood"},{"issue":"4","key":"3329_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378(4):331\u201344.","journal-title":"N Engl J Med"},{"issue":"2","key":"3329_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.21.01281","volume":"41","author":"LM Fornecker","year":"2023","unstructured":"Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J Clin Oncol. 2023;41(2):327\u201335.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3329_CR27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","volume":"9","author":"LJ Bryan","year":"2023","unstructured":"Bryan LJ, Casulo C, Allen PB, Smith SE, Savas H, Dillehay GL, et al. Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial. JAMA Oncol. 2023;9(5):683\u201391.","journal-title":"JAMA Oncol"},{"issue":"4","key":"3329_CR28","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s00259-020-05015-2","volume":"48","author":"G Manson","year":"2021","unstructured":"Manson G, Brice P, Herbaux C, Silva MG, Bouabdallah K, Deau B, et al. Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma. Eur J Nucl Med Mol I. 2021;48(4):1144\u201353.","journal-title":"Eur J Nucl Med Mol I"},{"issue":"8","key":"3329_CR29","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3324\/haematol.2022.282266","volume":"108","author":"K Ding","year":"2023","unstructured":"Ding K, Liu H, Ma J, Yang H, Cao L, Wang H, et al. Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial. Haematologica. 2023;108(8):2146\u201354.","journal-title":"Haematologica"},{"issue":"5","key":"3329_CR30","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s41409-020-01164-y","volume":"56","author":"B Bai","year":"2021","unstructured":"Bai B, Wang XX, Gao Y, Li PF, He HX, Ping LQ, et al. Prior anti-PD-1 therapy as a risk factor for life-threatening peri-engraftment respiratory distress syndrome in patients undergoing autologous stem cell transplantation. Bone Marrow Transpl. 2021;56(5):1151\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"Suppl","key":"3329_CR31","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/01.HS9.0000847232.50505.64","volume":"6","author":"NSV Mochkin","year":"2022","unstructured":"Mochkin NSV, Protopopova Y, Demina E, Melnichenko V, Bogatyrev V, Samoylova A, Mamedova A, Rukavitsyn A, Bannikova A, Smirnova E, Shorokhov N. Feasibility of ASCT after anti PD-1 therapy for R\/R classical Hodgkin lymphoma. Hemasphere. 2022;6(Suppl):981\u20132.","journal-title":"Hemasphere"},{"issue":"1","key":"3329_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41409-022-01849-6","volume":"58","author":"G ElGohary","year":"2023","unstructured":"ElGohary G, Toor AA, Gergis U. Engraftment syndrome after allogeneic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transplant. 2023;58(1):1\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"3329_CR33","first-page":"194","volume":"79","author":"K Poonsombudlert","year":"2020","unstructured":"Poonsombudlert K, Kewcharoen J, Prueksapraopong C, Limpruttidham N. Engraftment syndrome and acute graft-versus-host disease: a meta-analysis. Hawaii J Health Soc Welf. 2020;79(6):194\u2013201.","journal-title":"Hawaii J Health Soc Welf"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03329-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03329-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03329-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T18:04:08Z","timestamp":1710093848000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03329-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3329"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03329-8","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"10 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study secured approval from Ethics Committee of Peking University Cancer Hospital and Institute (No. 2019YJZ68) and was executed in alignment with the Declaration of Helsinki and Good Clinical Practice guidelines. All participants provided informed consent. The trial is registered at ClinicalTrials.gov under the identifier NCT04239170.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}